On this page
Batten disease (CLN6)
This condition is part of a group known as neuronal ceroid lipofuscinoses (NCLs). It typically causes progressive loss of vision, seizures, and a decline in motor and cognitive skills, often appearing in childhood. It is an inherited disorder affecting both males and females.
Available at Jeen Health
Clinical tests that include this
Overview
Batten disease (CLN6) is a lysosomal storage disorder, a type of condition where cells have difficulty processing and recycling waste products. This leads to the harmful accumulation of fatty substances called lipopigments (ceroid and lipofuscin) within cells, particularly in the brain and retina [PMID:33678564]. These deposits interfere with normal cell function, causing damage and death to nerve cells over time.
The condition is progressive, meaning symptoms worsen over time. There are several forms of Batten disease, each caused by different gene changes. The specific variant associated with the CLN6 gene is often referred to as variant late infantile NCL (vLINCL) or CLN6 disease, though it can also present in early-juvenile forms [PMID:33678564]. This particular form tends to manifest in early to mid-childhood.
Symptoms & clinical features
The symptoms of Batten disease (CLN6) typically begin between 18 months and 8 years of age. Initial signs often include developmental regression, such as a loss of previously acquired speech or motor skills. Vision impairment is a common early symptom, often progressing to blindness [PMID:20301344]. Seizures are also a predominant feature, which can be difficult to control.
As the condition advances, affected individuals typically experience a decline in cognitive abilities, leading to intellectual disability. Motor skills progressively worsen, resulting in difficulties with coordination, balance, and movement (ataxia), eventually leading to loss of independent walking. Other features can include sleep disturbances, behavioural changes, and difficulties with swallowing.
Video: Genetics 101
Affected organs
Batten disease (CLN6) primarily affects the central nervous system, including the brain and spinal cord. The accumulation of lipopigments within nerve cells in these areas leads to widespread neuronal damage. The retina, the light-sensitive tissue at the back of the eye, is also significantly affected, contributing to vision loss.
While the main impact is on neurological function, the harmful deposits can occur in cells throughout the body. However, the most severe and clinically significant effects are observed in the nervous system and eyes due to the crucial role of healthy nerve cells in these systems.
Risks & severity
Batten disease (CLN6) is a severe, progressive neurodegenerative disorder. The severity and rate of progression can vary between individuals, even within the same subtype, but the condition generally leads to significant disability and a shortened lifespan. The onset of symptoms typically occurs in early to mid-childhood, and the progression usually results in complete dependence for daily activities.
Life expectancy is significantly reduced, with affected individuals often surviving into late childhood or adolescence, though some may live longer. The exact prevalence of Batten disease (CLN6) is not well established, but it is considered a rare disease. Research into understanding the disease's progression and potential treatments is ongoing.
Genetic causes
Batten disease (CLN6) is caused by pathogenic changes in the CLN6 gene. This gene provides instructions for making a protein found primarily in the endoplasmic reticulum, a network of membranes within cells involved in protein and lipid synthesis. While the exact function of the CLN6 protein is not fully understood, it is thought to be involved in the movement of specific proteins and fats between the endoplasmic reticulum and lysosomes [PMID:20301344]. Lysosomes are often called the 'recycling centres' of the cell, breaking down waste products.
When the CLN6 gene contains a pathogenic variant, it leads to a faulty or absent CLN6 protein. This disruption in cellular transport and lysosomal function results in the accumulation of lipopigments within cells, particularly nerve cells. The toxic build-up of these substances impairs nerve cell function and eventually causes cell death, leading to the neurological symptoms characteristic of Batten disease (CLN6).
- CLN6 CLN6 transmembrane ER proteinThe CLN6 gene provides instructions for a protein located in the endoplasmic reticulum, which is thought to be involved in the transport of various cellular components.
Inheritance pattern
Batten disease (CLN6) is inherited in an autosomal recessive pattern. This means that an individual must inherit two copies of the altered CLN6 gene - one from each parent - to develop the condition.
If a person inherits only one copy of the altered gene, they are considered a 'carrier'. Carriers typically do not show symptoms of the disease themselves because their unaffected copy of the gene can compensate. However, when two carriers have a child, there is a 25% (1 in 4) chance with each pregnancy that their child will inherit two altered copies of the gene and develop Batten disease (CLN6). There is also a 50% chance the child will be a carrier, and a 25% chance the child will inherit two unaffected copies of the gene.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosing Batten disease (CLN6) typically involves a combination of clinical evaluation, neurological assessments, and genetic testing. If a child presents with symptoms such as progressive vision loss, developmental regression, and seizures, a specialist paediatrician or neurologist may suspect a lysosomal storage disorder.
Genetic testing is the definitive method to confirm a diagnosis and identify the specific gene involved, such as CLN6. This involves taking a blood or saliva sample to analyse the DNA. In the UK, genetic testing for suspected inherited neurological disorders like Batten disease is carried out through the NHS Genomic Medicine Service. Referrals to clinical genetics services for testing can be made by various specialists, and the relevant NHS R-codes would be used for ordering specific genomic tests once clinically indicated. Electron microscopy on a skin biopsy might also show characteristic 'fingerprint' inclusions within cells, which can support the diagnosis before genetic confirmation [PMID:33678564].
Management & lifestyle
Currently, there is no cure for Batten disease (CLN6), and management focuses on providing supportive care to alleviate symptoms and improve quality of life. This includes managing seizures with anti-epileptic medications, addressing motor difficulties with physiotherapy and occupational therapy, and supporting speech and communication needs.
Nutritional support may be necessary as swallowing difficulties progress. Regular reviews with a paediatric neurologist and a multidisciplinary team are essential to monitor the disease progression and adapt care as needed. Families affected by Batten disease can access support and information from specialist genetic counsellors within the NHS, who can help explain the condition, its inheritance, and available support services.
UK care pathway
In the UK, individuals suspected of having an inherited neurological condition like Batten disease (CLN6) are typically referred to a specialist consultant, often a paediatric neurologist. If clinical suspicion is high, the patient may be referred to an NHS Clinical Genetics service. This service can arrange for genomic testing through the NHS Genomic Medicine Service, utilising specific R-codes for panels covering neurodegenerative disorders or NCLs. Genetic counsellors are an integral part of this pathway, providing crucial information and support to families regarding diagnosis, inheritance, and implications for other family members.
Frequently asked questions
What is the typical age of onset for Batten disease (CLN6)?
Symptoms of Batten disease (CLN6) typically begin in early to mid-childhood, often between 18 months and 8 years of age. The specific age can vary, but it generally presents during these formative years.
Can Batten disease (CLN6) affect adults?
While symptoms typically manifest in childhood, the term 'Batten disease' encompasses several forms. CLN6 disease is generally a childhood-onset condition, but other very rare forms of NCL can have later onset in adulthood. However, CLN6 specifically is associated with paediatric presentation.
Is there a cure for Batten disease (CLN6)?
Currently, there is no cure for Batten disease (CLN6). Treatment focuses on managing symptoms to improve comfort and quality of life for affected individuals, often involving a combination of medications and supportive therapies.
How is Batten disease (CLN6) inherited?
Batten disease (CLN6) is inherited in an autosomal recessive manner. This means a child must inherit two copies of the altered CLN6 gene, one from each parent, to develop the condition. Parents who each carry one altered gene typically do not show symptoms themselves.
Where can I find support if my child is diagnosed with Batten disease (CLN6)?
In the UK, support is available through specialist teams at the NHS, including genetic counsellors. Organisations such as the Batten Disease Family Association (BDFA) also provide valuable information, support, and a community for affected families.